BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/26/2024 7:09:00 AM | Browse: 25 | Download: 0
Category |
Immunology |
Manuscript Type |
Editorial |
Article Title |
Early identification and multidisciplinary management of immune checkpoint inhibitors associated colitis can improve patient outcomes
|
Manuscript Source |
Invited Manuscript |
All Author List |
Liang Wang, Sheng-Mei Zhang and Xiao-Qian Chen |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
2021 Key Topic of Qinghai Provincial Health System–Guiding Plan Topic |
No. 2021-WJZDX-43 |
|
Corresponding Author |
Xiao-Qian Chen, Department of Gastrointestinal Oncology Surgery, The Affiliated Hospital of Qinghai University, The Affiliated Cancer Hospital of Qinghai University, No. 29 Tongren Road, Xining 810000, Qinghai Province, China. cxq925@163.com |
Key Words |
Immune checkpoint inhibitors; Immune-related adverse events; Immune checkpoint inhibitor-associated colitis; Immunotherapy; Multidisciplinary management |
Core Tip |
The application of various immune checkpoint inhibitors (ICIs) in treating various malignant tumors has yielded remarkable clinical efficacy, significantly improving patient prognosis. However, while ICIs strengthen anti-tumor immunity, they can also induce autoimmune damage and immune-related adverse events (irAEs), with immune checkpoint inhibitor (ICI)-associated colitis being relatively common. This condition may lead to treatment interruptions, drug discontinuation, and reduced treatment efficacy. Severe irAEs can even be life-threatening. Thus, vigilance for ICI-associated colitis is essential when patients exhibit symptoms like diarrhea and abdominal pain during or after ICI treatment. Early identification, multidisciplinary management, and continuous monitoring are critical to improving patient outcomes. |
Citation |
Wang L, Zhang SM, Chen XQ. Early identification and multidisciplinary management of immune checkpoint inhibitors associated colitis can improve patient outcomes. World J Gastrointest Surg 2024; In press |
|
Received |
|
2024-07-15 05:44 |
|
Peer-Review Started |
|
2024-07-14 10:16 |
|
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-10-28 07:50 |
|
Revised |
|
2024-11-09 12:34 |
|
Second Decision |
|
2024-11-26 02:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-11-26 07:09 |
|
Articles in Press |
|
2024-11-26 07:09 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-11-30 02:54 |
ISSN |
1948-9366 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345